Cystic Fibrosis Foundation
6931 Arlington Road
41 articles with Cystic Fibrosis Foundation
the Cystic Fibrosis Registry Global Harmonization Group, including the Cystic Fibrosis Foundation, published findings from the first global study on the impact of COVID-19 on children with cystic fibrosis.
the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.
The Cystic Fibrosis Registry Global Harmonization Group, including the CF Foundation, published in the Journal of Cystic Fibrosis updated data on the impact of COVID-19 on people with cystic fibrosis.
Today, the Cystic Fibrosis Foundation announced a new research award of up to $2.4 million to Calithera Biosciences Inc. to advance a potential treatment to reduce infections in the lungs of people with cystic fibrosis. Individuals with CF who have chronic infections are at greater risk for worsening, life-threatening lung disease,
CF Foundation Commits up to $14 Million in Funding to Expand Research Agreement With Synspira Therapeutics
Today, the Cystic Fibrosis Foundation announced it is expanding its research collaboration with Synspira Therapeutics Inc., committing up to $14 million in additional funding to develop a non-porcine enzyme replacement therapy and a novel treatment to help fight drug-resistant infections. The new fun
33 Organizations Representing Millions of Patients Urge Policymakers to Adopt "Patient-First" Policy Agenda
A coalition of 33 organizations representing millions of people with pre-existing conditions launched an unprecedented effort by releasing their top priorities for the next Administration.
Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis
The Cystic Fibrosis Foundation announced a collaboration with Longwood Fund, a biotech-focused venture capital firm, to accelerate innovative therapies for cystic fibrosis.
CF Foundation Invests up to $14M in Effort to Solve Key Challenges to Gene Delivery in Cystic Fibrosis
The Cystic Fibrosis Foundation announced an investment of up to $14 million in 4D Molecular Therapeutics to develop a customized vehicle to deliver a healthy cystic fibrosis transmembrane conductance regulator gene into the lung cells of people with cystic fibrosis.
4D Molecular Therapeutics, a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced a new agreement with Cystic Fibrosis Foundation to develop precision gene medicines for cystic fibrosis.
Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF
Potential first in a new class of antimicrobial drugs shown to have potent activity against CF-related pathogens in the lab
Collaborative effort identifies 40 cases of COVID-19 across eight countries; outcomes for this high-risk population were reported in the Journal of Cystic Fibrosis
Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement to Develop Broad-spectrum Enzyme Replacement for Malabsorption Syndromes
FRAMINGHAM, Mass. , Feb. 12, 2020 /PRNewswire/ -- Synspira Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases, announced today the company has signed an agreement with the Cystic Fibrosis Foundation to support the development of SNSP003, Synspira's orally delivered non-porci
Groupware Technology, Inc. announced it is the recipient of the Corporate Breath Award from the Northern California Chapter of the Cystic Fibrosis Foundation.
The Cystic Fibrosis Foundation unveiled its Path to a Cure, an ambitious research agenda to deliver treatments for the underlying cause of the disease and a cure for every person with cystic fibrosis (CF).
AbbVie will work to develop a cystic fibrosis transmembrane conductance regulator potentiator compound that it licensed from the Foundation.
Cystic Fibrosis Foundation Statement on FDA Approval of TRIKAFTA, the First Triple-Combination Therapy for the Most Common CF Mutation
FDA approval of TRIKAFTA, the highly effective and highly anticipated triple-combination CFTR modulator, marks the start of a new era in cystic fibrosis.
The Department of Homeland Security finalized a new rule that will deter use of vital services for some immigrant populations.
The Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International extended its current collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko™ Therapy
Phase 2 Study of PTI-428 + Symdeko Planned to Initiate in 3Q'18.